[Post-COVID-19 asthenic syndrome]

Area of Science:

• Neurology
• Pharmacology
• Infectious Diseases

Background:

• Asthenic syndrome frequently occurs in the post-COVID-19 period.
• Understanding the features and therapeutic options for post-COVID asthenia is crucial.

Purpose of the Study:

• To investigate the characteristics of asthenic syndrome in post-COVID-19 patients.
• To evaluate the efficacy of ethylmethylhydroxypyridine succinate (Neurox) in managing post-COVID asthenia.

Main Methods:

• A randomized study involving 129 patients post-COVID-19.
• Patients received either ethylmethylhydroxypyridine succinate (Neurox) or standard medical drugs (MD) for 4 weeks.
• Assessment included visual-analog scale (VAS), Multidimensional Fatigue Inventory (MFI-20), Mini-Mental State Examination (MMSE), and Kerdo index.

Main Results:

• Significant improvements in asthenia symptoms (VAS, MFI-20) were observed in the Neurox group.
• No significant changes in vegetative tone (Kerdo index) were noted in either group.
• Cognitive function decline (MMSE) in both groups may be linked to asthenia-related pseudocognitive deficits.

Conclusions:

• Asthenic syndrome is highly prevalent after COVID-19 infection.
• Treatment with ethylmethylhydroxypyridine succinate (Neurox) demonstrated a reduction in the severity and manifestation of asthenia symptoms.